相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low-dose Btk inhibitors selectively block platelet activation by CLEC-2
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2021)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
Steven P. Treon et al.
BLOOD (2020)
Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction
Thomas Menter et al.
HISTOPATHOLOGY (2020)
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19
Ishan Paranjpe et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Platelets Fuel the Inflammasome Activation of Innate Immune Cells
Verena Rolfes et al.
CELL REPORTS (2020)
Thromboinflammation and the hypercoagulability of COVID-19
Jean M. Connors et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
ISTH interim guidance on recognition and management of coagulopathy in COVID-19
Jecko Thachil et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia
David Lillicrap
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
Ning Tang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Yan Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle et al.
AUTOIMMUNITY REVIEWS (2020)
The dual role of platelet-innate immune cell interactions in thrombo-inflammation
Julie Rayes et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
An NLRP3 inflammasome-triggered cytokine storm contributes to Streptococcal toxic shock-like syndrome (STSLS)
Lan Lin et al.
PLOS PATHOGENS (2019)
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib
Elizabeth M. Kander et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans
Kristina Busygina et al.
BLOOD (2018)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Xiaojun Huang et al.
CANCER MEDICINE (2018)
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Lisa S. Chen et al.
BLOOD (2018)
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
M. Ruella et al.
LEUKEMIA (2017)
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
M. Montillo et al.
BLOOD CANCER JOURNAL (2017)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis
Holly Payne et al.
BLOOD (2017)
The cytokine storm of severe influenza and development of immunomodulatory therapy
Qiang Liu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization
Viola Lorenz et al.
BLOOD (2015)
Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets
Jessica R. Hitchcock et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury
Minako Ito et al.
NATURE COMMUNICATIONS (2015)
CLEC-2 expression is maintained on activated platelets and on platelet microparticles
Eelo Gitz et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Combined In Vivo Depletion of Glycoprotein VI and C-Type Lectin-Like Receptor 2 Severely Compromises Hemostasis and Abrogates Arterial Thrombosis in Mice
Markus Bender et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Ibrutinib and novel BTK inhibitors in clinical development
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo et al.
LANCET ONCOLOGY (2013)
Thrombosis as an intravascular effector of innate immunity
Bernd Engelmann et al.
NATURE REVIEWS IMMUNOLOGY (2013)
CLEC-2 is not required for platelet aggregation at arteriolar shear
C. E. Hughes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets
J. C. Spalton et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
分享论文
